Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for the treatment of acute coronary syndrome: A prospective, open-label, randomized, controlled study in Korean patients

Clinical Therapeutics

Volumn 31, Issue 8, 2009, Pages 1804-1811

  Choi, Dong Hyun ^a   Suh, Jung Won ^a   Park, Kyung Woo ^a   Kang, Hyun Jae ^a   Kim, Hyo Soo ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

abciximab; acute coronary syndrome; platelet aggregation

Indexed keywords

ABCIXIMAB; CLONITAB; GENERIC DRUG; HEPARIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BIOEQUIVALENCE; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG TOLERABILITY; EX VIVO STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; RETROPERITONEAL HEMORRHAGE; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT REFUSAL;

ACUTE CORONARY SYNDROME; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUGS, GENERIC; FEMALE; HEMORRHAGE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; KOREA; MALE; MIDDLE AGED; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; RETROPERITONEAL SPACE; THERAPEUTIC EQUIVALENCY;

EID: 72249095909     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.08.021     Document Type: Article

References (17)

1. Schömig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 334 (1996) 1084-1089
2. Ndrepepa G., Kastrati A., Mehilli J., et al. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: Results of the ISAR-REACT 2 randomized trial. Eur Heart J. 29 (2008) 455-461
3. Löfgren H. The global biopharma industry and the rise of Indian drug multinationals: Implications for Australian generics policy. Aust New Zealand Health Policy 4 (2007) 10
4. Moon J.Y., Kim W., Kim J.H., et al. A multicenter, randomized, open-label, therapeutic, and exploratory trial to evaluate the tolerability and efficacy of platelet glycoprotein IIb/IIIa receptor blocker (Clotinab) in high-risk patients with percutaneous coronary intervention. Yonsei Med J. 49 (2008) 389-399
5. Smith J.W., Steinhubl S.R., Lincoff A.M., et al. Rapid platelet-function assay: An automated and quantitative cartridge-based method. Circulation 99 (1999) 620-625
6. Wheeler G.L., Braden G.A., Steinhubl S.R., et al. The Ultegra rapid platelet-function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J. 143 (2002) 602-611
7. Kralisz P., Dobrzycki S., Nowak K., et al. Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction. Kardiol Pol. 60 (2004) 459-467
8. Cannon C.P., Battler A., Brindis R.G., et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol. 38 (2001) 2114-2130
9. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 330 (1994) 956-961
10. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 336 (1997) 1689-1696
11. The PRISM-PLUS (Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction [published correction appears in N Engl J Med. 1998;339:415]. N Engl J Med. 338 (1998) 1488-1497
12. The PURSUIT (Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 339 (1998) 436-443
13. The PARAGON (Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network) Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 97 (1998) 2386-2395
14. The PRISM (Platelet Receptor Inhibition in Ischemic Syndrome Management) Study Investigators. A comparison of aspirin plus tiro-fiban with aspirin plus heparin for unstable angina. N Engl J Med. 338 (1998) 1498-1505
15. Anderson J.L., Adams C.D., Antman E.M., et al., American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction), American College of Emergency Physicians, Society for Cardiovascular Angiog-raphy and Interventions, Society of Thoracic Surgeons, American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine [published correction appears in J Am Coll Cardiol. 2008;51:974]. J Am Coll Cardiol. 50 (2007) e1-e157
16. Lee S.H., Kim Y.J., Kim W., et al., Korean Acute Myocardial Infarction Registry Investigators. Clinical outcomes and therapeutic strategy in patients with acute myocardial infarction according to renal function: Data from the Korean Acute Myocardial Infarction Registry. Circ J. 72 (2008) 1410-1418
17. Lee K.H., Jeong M.H., Ahn Y.K., et al., Korea Acute Myocardial Infarction Registry (KAMIR) Investigators. Gender differences of success rate of percutaneous coronary intervention and short term cardiac events in Korea Acute Myocardial Infarction Registry. Int J Cardiol. 130 (2008) 227-234